SCHEMBL26186325

SCHEMBL26186325

N#Cc1cccc(Nc2cc(NO)ccn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.50
ABCG2 Q9UNQ0 3/20 0.46
GRM4 Q14833 1/20 0.46
SLC2A1 P11166 2/20 0.44
SYK P43405 2/20 0.44
CDC7 O00311 1/20 0.44
CDK4 P11802 1/20 0.43
CDK2 P24941 1/20 0.43
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
KCNH2 Q12809 1/20 0.42
TNIK Q9UKE5 1/20 0.42
F9 P00740 1/20 0.42
IDO1 P14902 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14042535 0.81 MAPT (0.58) ABCG2GRM4ALDH1A1MAPTIDO1
SCHEMBL26186351 0.81 IDH1 (0.42)
SCHEMBL26186355 0.81 SYK (0.39) BRAFABCG2SLC2A1SYKKDR
SCHEMBL4387590 0.79 SYK (0.56) BRAFABCG2GRM4SYKCDK4
SCHEMBL10289572 0.79 GRM4 (0.57) ABCG2GRM4SLC2A1SYKCDC7
SCHEMBL26186627 0.79 ABCG2 (0.45) BRAFABCG2GRM4SLC2A1SYK
SCHEMBL26186328 0.78 JAK2 (0.55) CDK2MAPTAURKAIDO1MEN1
SCHEMBL24173759 0.78 HTR3E (0.56) BRAFGRM4CDK4CDK2KDR
SCHEMBL26186322 0.78 NPC1 (0.50) ABCG2GRM4CDK2ALDH1A1MAPT
SCHEMBL3951723 0.77 HTR3E (0.55) ABCG2MAPTAURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-31 US disclosed
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY P2RX2, P2RX5, P2RX3 BRAF 3188/4885ABCG2 27/4885GRM4 974/4885
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS P2RX2, P2RX4, P2RX5 BRAF 1792/4885ABCG2 1390/4885GRM4 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.